ClinicalTrials.gg
DrugCombination product

Opemalirsen clinical trials

studies test it
4
open now
0
in phase 3
0
first study started
2020

How each study uses opemalirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

AZD2373 subcutaneous injection
2

Studies by the year they started

4 studies that test it; most in 2025 (2)

Studies that test opemalirsen, by start year
YearStudies
20201
20221
20252

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

Who runs them

Industry 4 · Other 0

AstraZeneca (4)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test opemalirsen.

Studies

Open first, then newest update. How each study uses opemalirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Codes

What other systems call opemalirsen · ClinicalTrials.gg INT017944

  • UNII (FDA) SVT2GC4GOIOPEMALIRSENOne source FDA
  • NCI Thesaurus C203038OpemalirsenOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.